Highlights

  • Immutep (ASX:IMM) reported a pooled analysis showing a 7.7-month median overall survival difference among patients with lymphocyte response to efti treatment.
  • The TACTI-004 Phase III lung cancer trial was discontinued in March 2026 following an interim futility analysis.
  • Immutep held approximately A$68.9 million in cash and term deposits at 30 June 2026.
  • The company is progressing additional programs including INSIGHT-003, EFTISARC-NEO and IMP761.

Immutep (ASX:IMM) enters the second half of 2026 attempting to rebuild investor confidence after a major setback to its lead clinical program. The company experienced a sharp market reaction in March after its TACTI-004 Phase III lung cancer study was discontinued following an interim futility analysis. Several months later, Immutep presented survival data suggesting a potential biomarker link for patients responding to eftilagimod alfa (efti). The company is now focused on determining whether that scientific signal can support future development pathways.

Latest Development

The key setback came on 13 March 2026, when Immutep announced that TACTI-004, a randomised, double-blind Phase III study evaluating eftilagimod alfa combined with Merck's Keytruda and chemotherapy in first-line advanced non-small cell lung cancer, would be discontinued. The Independent Data Monitoring Committee recommended stopping the trial after a planned interim futility analysis.

The study was designed to enrol approximately 756 patients across more than 150 sites in over 25 countries. Interim results from 173 evaluable patients showed an objective response rate of 42.9 per cent in the efti treatment arm compared with 55.1 per cent in the control arm.

On 28 May 2026, Immutep reported a pooled analysis across five earlier efti studies showing that patients who developed a lymphocyte response following efti treatment recorded median overall survival 7.7 months longer than non-responders. The company reported the association as statistically significant, with a p-value of 0.00171.

What the Numbers Show

The pooled analysis included data from five clinical studies: TACTI-mel, TACTI-002, TACTI-003, AIPAC and AIPAC-003, covering indications including lung cancer, head and neck cancer, breast cancer and melanoma.

The analysis supports Immutep's view that immune activation following efti treatment may help identify patients more likely to benefit from therapy. However, the findings are based on retrospective analysis and require further validation through controlled studies.

The company's financial position remains an important factor. At 30 June 2026, Immutep held approximately A$68.9 million in cash and term deposits. Net operating cash outflow was A$38.9 million during the June quarter, partly reflecting costs associated with winding down TACTI-004. Management expects the current cash balance to support operations into the first half of calendar 2028.

Why It Matters

Immutep's development strategy is based around LAG-3, an immune checkpoint pathway that plays a role in regulating immune responses. Efti is designed to activate antigen-presenting cells and enhance immune system activity alongside checkpoint inhibitor treatments.

TACTI-004 was intended to provide large-scale clinical validation for efti in first-line lung cancer. Its discontinuation has changed the development pathway and raised questions around whether earlier positive signals from smaller studies can be replicated in larger randomised settings.

The biomarker analysis provides a possible explanation for differences in patient responses, but the company now needs additional evidence to establish whether the signal can guide future clinical development and partnerships.

Growth Catalysts

Despite the TACTI-004 outcome, Immutep continues to progress several programs. INSIGHT-003, an investigator-initiated Phase I study in non-squamous non-small cell lung cancer, reported a median overall survival of 30.9 months across 51 patients.

The EFTISARC-NEO Phase II study in soft tissue sarcoma achieved its primary objective and received Orphan Drug designation. Quality-of-life data from the study has also been accepted for presentation at ESMO Congress 2026.

Beyond oncology, Immutep is developing IMP761, an agonist antibody targeting autoimmune disease. First-in-human Phase I results presented at EULAR 2026 showed favourable safety across tested doses and pharmacodynamic activity, with additional updates expected in the second half of calendar 2026.

Risks Investors Should Watch

The largest risk is whether the biomarker findings can be confirmed in future clinical studies. Retrospective pooled analyses can identify potential signals but do not provide the same level of evidence as successful randomised trials.

Immutep is also conducting a root-cause analysis into the TACTI-004 outcome, including differences in immune activation profiles compared with earlier studies. A neoadjuvant breast cancer study remains paused pending further assessment.

The company also faces legal and commercial uncertainties, including a securities class action following the share-price decline and the termination of Novartis' ieramilimab out-licence. While the cash position provides operating runway, the development pipeline is now narrower and requires successful execution.

What Happens Next

The next important milestones will focus on clinical evidence and strategic direction. Investors will monitor the outcome of the TACTI-004 root-cause review, including implications for future efti programs and the paused breast cancer study.

Further updates from IMP761 are expected in the second half of calendar 2026, while additional data from EFTISARC-NEO and other programs may provide further information on pipeline potential.

With funding runway extending into 2028, Immutep has time to progress its programs, but future valuation support will depend on controlled clinical data and potential partner interest.

Conclusion

Immutep (ASX:IMM) enters the second half of 2026 with a combination of scientific opportunity and significant uncertainty. The 7.7-month survival signal from pooled efti data provides a potential development pathway, while the TACTI-004 Phase III failure has changed the company's near-term outlook. The company retains a meaningful cash balance and several ongoing clinical programs, but rebuilding investor confidence will require further evidence that the biomarker findings can translate into repeatable clinical outcomes.